bupropion has been researched along with Idiopathic Parkinson Disease in 11 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on a 57-year-old woman, diagnosed with Parkinson's disease, whose panic disorder showed marked improvement after introduction of bupropion, a norepinephrine-dopamine reuptake inhibitor." | 7.74 | Treatment of panic disorder with bupropion in a patient with Parkinson's disease. ( Bäcker, A; Gebhardt, S; Krieg, JC; Röttgers, H; Schu, U, 2008) |
| "The role of dopamine agonists in the treatment of depression is still being explored because of no sufficient number of controlled studies in this area." | 5.36 | Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. ( Durst, R; Raskin, S, 2010) |
| "Bupropion has a unique mechanism of action: inhibition of the presynaptic reuptake of dopamine in addition to noradrenergic activity." | 5.31 | [Successful treatment of depression in a Parkinson disease patient with bupropion]. ( Leentjens, AF; Verhey, FR; Vreeling, FW, 2000) |
| "We report on a 57-year-old woman, diagnosed with Parkinson's disease, whose panic disorder showed marked improvement after introduction of bupropion, a norepinephrine-dopamine reuptake inhibitor." | 3.74 | Treatment of panic disorder with bupropion in a patient with Parkinson's disease. ( Bäcker, A; Gebhardt, S; Krieg, JC; Röttgers, H; Schu, U, 2008) |
| "Selegiline is a selective monoamine oxidase inhibitor used in the treatment of Parkinson's disease." | 2.40 | Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. ( Alexander, B; Ritter, JL, 1997) |
| "The role of dopamine agonists in the treatment of depression is still being explored because of no sufficient number of controlled studies in this area." | 1.36 | Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. ( Durst, R; Raskin, S, 2010) |
| "Bupropion has a unique mechanism of action: inhibition of the presynaptic reuptake of dopamine in addition to noradrenergic activity." | 1.31 | [Successful treatment of depression in a Parkinson disease patient with bupropion]. ( Leentjens, AF; Verhey, FR; Vreeling, FW, 2000) |
| "Bupropion is an antidepressant, thought to be an indirect dopaminergic agonist." | 1.27 | Bupropion in Parkinson's disease. ( Goetz, CG; Klawans, HL; Tanner, CM, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Vismara, M | 1 |
| Benatti, B | 1 |
| Nicolini, G | 1 |
| Cova, I | 1 |
| Monfrini, E | 1 |
| Di Fonzo, A | 1 |
| Fetoni, V | 1 |
| Viganò, CA | 1 |
| Priori, A | 1 |
| Dell'Osso, B | 1 |
| Ahn, BJ | 1 |
| Kwon, KY | 1 |
| Gebhardt, S | 1 |
| Röttgers, H | 1 |
| Bäcker, A | 1 |
| Schu, U | 1 |
| Krieg, JC | 1 |
| Raskin, S | 1 |
| Durst, R | 1 |
| Załuska, M | 1 |
| Dyduch, A | 1 |
| Benincasa, D | 1 |
| Pellicano, C | 1 |
| Fanciulli, A | 1 |
| Pontieri, FE | 1 |
| Grandas, F | 1 |
| López-Manzanares, L | 1 |
| Goetz, CG | 1 |
| Tanner, CM | 1 |
| Klawans, HL | 1 |
| Ritter, JL | 1 |
| Alexander, B | 1 |
| Leentjens, AF | 1 |
| Verhey, FR | 1 |
| Vreeling, FW | 1 |
| Liberzon, I | 1 |
| Dequardo, JR | 1 |
| Silk, KR | 1 |
2 reviews available for bupropion and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.
Topics: Antidepressive Agents; Apathy; Bupropion; Dopamine; Humans; Parkinson Disease | 2022 |
Retrospective study of selegiline-antidepressant drug interactions and a review of the literature.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Bu | 1997 |
9 other studies available for bupropion and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Elderly woman presenting with unusual propriospinal myoclonus triggered by drug-induced nausea and vomiting.
Topics: Aged, 80 and over; Alzheimer Disease; Bupropion; Dopamine Agents; Dopamine Uptake Inhibitors; Female | 2018 |
Treatment of panic disorder with bupropion in a patient with Parkinson's disease.
Topics: Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Female; Humans; Middle Aged; Pani | 2008 |
Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; Humans; | 2010 |
Bupropion in the treatment of depression in Parkinson's disease.
Topics: Aged; Antidepressive Agents, Second-Generation; Brain; Bupropion; Depressive Disorder; Female; Human | 2011 |
Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Bupropion; Compulsive Behavior; Dopamine Uptake Inhibitors; Femal | 2011 |
Bupropion-induced parkinsonism.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depression; Humans; Male; Middle Aged; Parkinso | 2007 |
Bupropion in Parkinson's disease.
Topics: Adult; Aged; Bupropion; Female; Humans; Male; Middle Aged; Parkinson Disease; Propiophenones | 1984 |
[Successful treatment of depression in a Parkinson disease patient with bupropion].
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; F | 2000 |
Bupropion and delirium.
Topics: Aged; Amantadine; Antidepressive Agents; Bupropion; Delirium; Depressive Disorder; Drug Therapy, Com | 1990 |